Bitnomial secures CFTC clearance to expand prediction markets
Bitnomial has secured regulatory clearance to roll out prediction markets for U.S. customers focused on crypto and economic outcomes.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Bitnomial has secured regulatory clearance to roll out prediction markets for U.S. customers focused on crypto and economic outcomes.
2025 delivered global conflict and political shockwaves - yet markets surged anyway.
Endeavour Silver Corp. (NYSE:EXK) reported full-year 2025 production of 6,486,661 ounces of silver and 37,164 ounces of gold, equivalent to 11.2 million silver equivalent ounces assuming an 80:1 ratio, representing a 48% increase from the prior year.
The Buckle (NYSE:BKE) reported robust sales performance for the five-week fiscal month ended January 3, 2026, a period encompassing the critical holiday shopping season.
Net sales increased 6.5% to $215.3 million from $202.1 million in the prior-year five-week period ended January 4, 2025.
CorMedix (NASDAQ:CRMD) reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, alongside initial fiscal 2026 guidance and program updates.
Menlo Park, California-based Personalis (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, reported unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025.
Beverly Hills, California-based AXIL Brands (NYSE:AXIL) reported net sales of $8.1 million for its fiscal second quarter ended November 30, 2025, marking a 5.2% increase from the year-ago period.
Neogen (NASDAQ:NEOG) shares are in focus after the food and animal safety leader reported second-quarter revenue of $224.7 million, a 2.8% decline from the previous year.
TD SYNNEX (NYSE:SNX) today announced robust financial results for its fiscal fourth quarter ended November 30, 2025, demonstrating solid growth across key metrics.
Shares of software supply chain platform JFrog (NASDAQ:FROG) fell 4.7% in morning trading on January 8, 2026, as part of a broader market rotation out of the technology sector.
The decline came amid profit-taking in high-growth tech stocks following a strong recent rally, particularly in artificial-intelligence-related names.
Acrivon Therapeutics (NASDAQ:ACRV) unveiled promising interim data from its lead oncology program on Thursday, demonstrating that its biomarker-driven approach can achieve significant results in patients with hard-to-treat serous endometrial cancer.
The company’s lead candidate, ACR-368, a selective CHK1/2 inhibitor, showed a 67% confirmed objective response rate (cORR) in a subset of patients identified by Acrivon’s proprietary "OncoSignature" biomarker.
Paramount (NASDAQ:PSKY) reaffirmed its $30-per-share cash offer for Warner Bros. Discovery on Thursday, resisting pressure to sweeten the deal even after WBD’s board dismissed the proposal as a risky "leveraged buyout."
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade